BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 21619694)

  • 1. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
    Wan Y; Wu W; Yin Z; Guan P; Zhou B
    BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
    Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
    PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.
    Cheng H; Ma B; Jiang R; Wang W; Guo H; Shen N; Li D; Zhao Q; Wang R; Yi P; Zhao Y; Liu Z; Huang T
    Mol Biol Rep; 2012 Sep; 39(9):9265-74. PubMed ID: 22729912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis.
    Duan X; Li J
    Medicine (Baltimore); 2017 Sep; 96(36):e7856. PubMed ID: 28885338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
    Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
    Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
    Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
    Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma.
    Zhang JN; Yi SH; Zhang XH; Liu XY; Mao Q; Li SQ; Xiong WH; Qiu YM; Chen T; Ge JW
    Genet Mol Res; 2012 Oct; 11(4):3618-28. PubMed ID: 23096687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk.
    Qin X; Peng Q; Tang W; Lao X; Chen Z; Lai H; Deng Y; Mo C; Sui J; Wu J; Zhai L; Yang S; Li S; Zhao J
    PLoS One; 2013; 8(9):e76031. PubMed ID: 24098760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
    Nan H; Qureshi AA; Hunter DJ; Han J
    Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.
    Hu Z; Jin G; Wang L; Chen F; Wang X; Shen H
    Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2717-23. PubMed ID: 18086778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
    Fang S; Krahe R; Lozano G; Han Y; Chen W; Post SM; Zhang B; Wilson CD; Bachinski LL; Strong LC; Amos CI
    PLoS One; 2010 May; 5(5):e10813. PubMed ID: 20520810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
    Han JY; Lee GK; Jang DH; Lee SY; Lee JS
    Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.
    Horikawa Y; Nadaoka J; Saito M; Kumazawa T; Inoue T; Yuasa T; Tsuchiya N; Nishiyama H; Ogawa O; Habuchi T
    Oncol Rep; 2008 Jul; 20(1):49-55. PubMed ID: 18575717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis.
    Ma Y; Bian J; Cao H
    PLoS One; 2013; 8(2):e56918. PubMed ID: 23451111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area.
    Huang CY; Su CT; Chu JS; Huang SP; Pu YS; Yang HY; Chung CJ; Wu CC; Hsueh YM
    Toxicol Appl Pharmacol; 2011 Dec; 257(3):349-55. PubMed ID: 21982800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
    Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
    Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
    Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.